© 2025 HSP News Service, L.L.C.
The more alcohol young women drink before motherhood, the greater their risk of future breast cancer, according to new research from Washington University School of Medicine in St. Louis. Previous studies have looked at breast cancer risk and alcohol consumption later in life or at the effect of...
Subcutaneous trastuzumab (not available in the United States) has been shown to have noninferior efficacy and similar pharmacokinetic and safety profiles compared with intravenous trastuzumab (Herceptin) in patients with early-stage HER2-positive breast cancer. In the PrefHer trial reported in...
Annual screening for breast cancer with magnetic resonance imaging (MRI) has been found to be cost-effective in women aged 30 to 60 years who are BRCA1 or BRCA2 carriers or who have a 50% chance of being a carrier, and such screening is recommended in these women by many authorities. It is unclear...
Anthracycline- and taxane-based three-drug chemotherapy regimens have proven benefit as adjuvant therapy for early-stage breast cancer. As reported in Journal of Clinical Oncology by Sandra M. Swain, MD, FACP, of Washington Cancer Institute–MedStar Washington Hospital Center, and colleagues,...
In a study reported in Journal of Clinical Oncology, Tomasz Huzarski, MD, PhD, of Pomeranian Medical University, Szczecin, Poland, and colleagues from the Polish Hereditary Breast Cancer Consortium assessed survival among women with early-onset breast cancer with and without BRCA1 mutation and...
Based on data from a multisite imaging trial involving more than 2,600 women, researchers say breast lesions categorized as “probably benign” on supplemental screening ultrasound could be reevaluated with imaging in 12 months, reducing patient anxiety, follow-up exams, and unnecessary...
In a study (the BEATRICE trial) reported in Lancet Oncology, David Cameron, MD, of the University of Edinburgh, and colleagues evaluated the strategy of adding the antiangiogenic agent bevacizumab (Avastin) to adjuvant chemotherapy in women with triple-negative breast cancer. The study showed that...
Despite taking a tailored risk assessment tool that factors in family history and personal habits, nearly 20% of women did not believe their breast cancer risk, according to a new study from the University of Michigan Comprehensive Cancer Center. The findings, published in Patient Education and...
A new analysis has found that breastfeeding for more than 6 months may safeguard nonsmoking mothers against breast cancer. However, the same does not seem to hold true for mothers who smoke. Published early online in the Journal of Clinical Nursing, the findings add to the list of benefits of...
A trial reported in Journal of Clinical Oncology by John P. Crown, MD, of the Irish Cooperative Oncology Research Group, and colleagues assessed the addition of the antiangiogenesis agent sunitinib (Sutent) to capecitabine (Xeloda) in patients with previously treated metastatic breast cancer who...
In a study reported in Lancet Oncology, Timothy Key, PhD, of Oxford University, and colleagues in the Endogenous Hormones and Breast Cancer Collaborative Group analyzed data from seven prospective studies to determine associations between sex hormones and risk of breast cancer in premenopausal...
In a study reported in Journal of Clinical Oncology, Kelly-Anne Phillips, MD, of Peter MacCallum Cancer Centre and University of Melbourne, and colleagues analyzed the association of adjuvant tamoxifen use and risk of contralateral breast cancer among women carrying BRCA1 and BRCA2 mutations in the ...
Long-term use of a calcium-channel blocker to treat hypertension is associated with higher breast cancer risk, according to a report published by JAMA Internal Medicine. The study assessed the relationships between the major classes of hypertensive agents and risk of the two most common histologic...
Many factors play into why women diagnosed with breast cancer often choose overly aggressive treatment even when there is little evidence to show clinical benefit: the shock and fear of suddenly being confronted with a major health threat, the impression of having to make treatment decisions...
In the SoFEA trial, reported in Lancet Oncology by Stephen R.D. Johnston, PhD, FRCP, of Royal Marsden NHS Foundation Trust, and colleagues, postmenopausal women with advanced hormone receptor–positive breast cancer that progressed on nonsteroidal aromatase inhibitors were treated with the...
The addition of tomosynthesis to standard digital mammography resulted in a 30% reduction in overall recall rates among women being screened for breast cancer, according to a new study published online in Radiology. The results demonstrate that digital tomosynthesis is an effective tool in reducing ...
Surgery is not always necessary for women with a type of breast tissue abnormality associated with a higher risk of cancer, according to a new study published online in Radiology. Researchers said that periodic imaging and clinical exam are effective in these patients when radiology and pathology...
In an analysis of 5-year survival rates among black and white women diagnosed with breast cancer between 1991 and 2005, black women continued to have a lower rate of survival, with most of the difference related to factors including poorer health of black patients at diagnosis and more advanced...
In a phase II study evaluating three dosing regimens of nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) given with bevacizumab (Avastin), weekly dosing of nab-paclitaxel resulted in the highest overall response rate and longest progression-free survival. The schedule of nab-paclitaxel given...
Women who survive cancer have more frequent, severe, and troubling hot flashes than other women with menopausal symptoms, according to a study published online in Menopause, the journal of The North American Menopause Society (NAMS). But surprisingly, the cancer survivors fare better...
The RAPID trial compared accelerated partial-breast irradiation using three-dimensional (3D) conformal external-beam radiation therapy vs whole-breast irradiation in women with invasive or in situ breast cancer ≤ 3 cm. As reported by Ivo A. Olivotto, MD, FRCPC, of the British Columbia Cancer...
Different factors influence delay between diagnosis and first course of treatment for breast cancer for African American and white women, according to a recently published study in Cancer Epidemiology, Biomarkers & Prevention. The study used data from the Carolina Breast Cancer Study (CBCS)...
The American Society of Clinical Oncology (ASCO) issued a newly updated clinical practice guideline today on pharmacologic prevention interventions for premenopausal and postmenopausal women who are at increased risk for breast cancer. Compared to the previous version of the guideline, this third...
Two drugs were given Priority Review designation by FDA earlier this week. Obinutuzumab (GA101) was granted Priority Review for the treatment of chronic lymphocytic leukemia (CLL), based on final stage 1 data from the pivotal CLL11 trial. FDA also granted Priority Review to a pertuzumab (Perjeta)...
A novel pairing of two investigational cancer drugs in patients with recurrent ovarian cancer showed promising activity and had manageable toxicities, according to a phase I trial published online in the European Journal of Cancer. The combination of the poly(ADP-ribose) polymerase (PARP)...
A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment. In a report published online in the Journal...
Arm lymphedema affects approximately 30% of breast cancer survivors, with rates increasing with longer follow-up and cases presenting well beyond the active treatment period. Lymphedema is observed even with use of less-invasive surgical techniques for staging, and risk is further increased by such ...
According to a review of studies examining the impact of isoflavones in soyfoods on breast cancer risk, clinical evidence indicates that exposure to isoflavones, which are classified as both phytoestrogens and selective estrogen receptor modulators, has little effect on the markers of breast cancer ...
Members of Congress are considering two bills that could advance cures for breast cancer and provide better education for women grappling with decisions about their treatment options. Accelerating the End of Breast Cancer Act Accelerating the End of Breast Cancer Act of 2013 (S. 865/H.R. 1830)...
The phase III open-label PHARE trial, conducted in 156 centers in France, examined whether 6 months of adjuvant trastuzumab (Herceptin) was noninferior to 12 months of treatment in women with early HER2-positive breast cancer. As reported by Xavier Pivot, MD, of University Hospital Jean-Minjoz,...
Various studies have suggested that acetyl-L-carnitine, a natural compound involved in neuronal protection, may be effective in preventing and treating sensory neuropathy. Dawn L. Hershman, MD, MS, of Columbia University Medical Center, and colleagues recently assessed whether daily...
A new molecular pathway involving the gene ZNF365 has been identified, and abnormalities in that pathway may predict worse outcomes for patients with breast cancer, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. “Genomic...
A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a study presented at the Endocrine Society’s 95th Annual Meeting in San Francisco. The findings ...
A protein used by embryo cells during early development, and recently found in many different types of cancer, may serve as a switch regulating metastasis, according to researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center. The findings were ...
Available data suggest that younger age is an independent risk factor for disease recurrence and death in women with breast cancer. However, there has not been adequate study of the interaction of age with human epidermal growth factor receptor 2 (HER2) status or anti-HER2 treatment. In an analysis ...
Single nucleotide polymorphisms (SNPs) in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. ...
An Indiana University cancer researcher and his Canadian collaborator have discovered how normal breast precursor cells may be genetically vulnerable to developing into cancer. David Gilley, PhD, Associate Professor of Medical and Molecular Genetics at the IU School of Medicine and a researcher at ...
For patients with advanced breast cancer, positron-emission tomography (PET) and magnetic resonance imaging (MRI) can improve quality of life and survival by providing physicians with information on the effectiveness of chemotherapy prior to surgery, according to researchers presenting at the 2013...
Results from a multicenter phase II study of patients with locally advanced HER2-positive breast cancer who receive targeted therapy with trastuzumab (Herceptin) and lapatinib (Tykerb) “support the hypothesis that selected patients with HER2-positive tumors may not need...
A genomic profiling study of African American women with breast cancer found that about one in five carries an inherited abnormality in at least 1 of 18 genes associated with breast cancer susceptibility. Such mutations were more prevalent among women with aggressive triple-negative breast cancer,...
A European phase III clinical trial found that lymphedema was twice as common among women with sentinel lymph node–positive early breast cancer who had axillary lymph node dissection compared to those who had axillary radiotherapy. Overall and disease-free survival 5 years after treatment...
Low-dose weekly administration of paclitaxel resulted in equal progression-free survival but reduced overall toxicity compared to every-2-week dose-dense administration for women with higher-risk early-stage breast cancer who have undergone surgery, according to a phase III randomized trial....
Ten years of adjuvant treatment with tamoxifen reduces breast cancer recurrence and mortality among women treated for early-stage estrogen receptor (ER)–positive breast cancer, according to results of the British phase III aTTom study. These findings, presented at the 2013 ASCO Annual Meeting ...
The addition of everolimus (Afinitor), an mTOR inhibitor, to trastuzumab (Herceptin) and vinorelbine significantly extended progression-free survival in women with HER2-positive advanced breast cancer, compared to treatment with placebo plus trastuzumab and vinorelbine, in the phase III BOLERO-3...
A lack of clinical trials aimed specifically at younger patients with breast cancer could be partly to blame for their poor survival rates, according to a study published in the Journal of the National Cancer Institute. Study Details The study analyzed 2,956 women diagnosed with breast cancer...
A newly developed, single-step Raman spectroscopy algorithm has the potential to simultaneously detect microcalcifications and enable diagnosis of the associated breast lesions with high precision, according to data published in Cancer Research, a journal of the American Association for Cancer...
Under conditions of oxygen starvation often encountered by tumors, the epidermal growth factor receptor (EGFR) sends signals that thwart the development of tumor-suppressing microRNAs, an international team led by scientists at The University of Texas MD Anderson Cancer Center discovered. The...
Hologic, Inc, announced today that the U.S. Food and Drug Administration (FDA) has approved the use of C-View, a new low-dose two-dimensional (2D) imaging software. C-View 2D images may now be used in place of the conventional 2D exposure previously required as part of Hologic’s FDA-approved...
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers ...
Despite previous scientific studies suggesting that the diabetes drug metformin has anticancer properties, a new, first-of-its-kind study from Women’s College Hospital in Toronto has found the drug may not actually improve survival rates after breast cancer in certain patients. The study,...